Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF

R&D Systems | Catalog # 1906-SF

R&D Systems
100% Guarantee

Key Product Details

  • R&D Systems HEK293-derived Recombinant Human CRACC/SLAMF7 Fc Chimera Protein (1906-SF)
  • Quality control testing to verify active proteins with lot specific assays by in-house scientists
  • All R&D Systems proteins are covered with a 100% guarantee

Source

HEK293

Accession Number

Q9NQ25

Structure / Form

Disulfide-linked homodimer

Applications

Bioactivity
View all CRACC/SLAMF7 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human CRACC/SLAMF7 protein
Human SLAMF7
(Ser23-Met226)
Accession # Q9NQ25		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ser23

Predicted Molecular Mass

49 kDa

SDS-PAGE

65-75 kDa, reducing conditions

Activity

Measured by its ability to inhibit anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells (PBMC).
The ED50 for this effect is 1-6 μg/mL.

Reviewed Applications

Read 1 review rated 4 using 1906-SF in the following applications:

Scientific Data Images for Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF

Recombinant Human CRACC/SLAMF7 Fc Chimera Protein Bioactivity

Recombinant Human CRACC/SLAMF7 Fc Chimera Protein Bioactivity

Recombinant Human CRACC/SLAMF7 Fc Chimera (Catalog # 1906-SF) inhibits anti-CD3 antibody induced IFN-gamma secretion by human peripheral blood mononuclear cells. The ED50 for this effect is 2-10 μg/mL.
Recombinant Human CRACC/SLAMF7 Fc Chimera Protein SDS-PAGE

Recombinant Human CRACC/SLAMF7 Fc Chimera Protein SDS-PAGE

2 μg/lane of Recombinant Human CRACC/SLAMF7 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 65-75 kDa and 130-150 kDa, respectively.

Formulation, Preparation, and Storage

1906-SF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: CRACC/SLAMF7

CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CRACC consists of a 204 amino acid (aa) extracellular domain (ECD) with one Ig-like V-set domain and one Ig-like C2-set domain, a 21 aa transmembrane segment, and an 88 aa cytoplasmic domain with one immunoreceptor tyrosine-based switch motif (ITSM) (2, 3). Within the ECD, human CRACC shares 54% and 52% aa sequence identity with mouse and rat CRACC, respectively. There are seven known isoforms of CRACC which are distinguished by deletions and/or substitutions in both their ECD and cytoplasmic domains. CRACC is expressed on the surface of NK cells, CD8+ T cells, activated B cells, and mature dendritic cells (4, 5). Its homophilic interaction induces NK, CTL, and B cell activation (4-7). In human NK cells, activated CRACC transmits signals following association with the adaptor protein EAT-2 (8).

References

  1. Veillette, A. (2006) Immunol. Rev. 214:22.
  2. Tovar, V. et al. (2002) Immunogenetics 54:394.
  3. Murphy, J.J. et al. (2002) Biochem. J. 361:431.
  4. Bouchon, A. et al. (2001) J. Immunol. 167:5517.
  5. Lee, J.K. et al. (2007) J. Immunol. 179:4672.
  6. Kumaresan, P.R. et al. (2002) Mol. Immunol. 39:1.
  7. Stark, S. and C. Watzl (2006) Int. Immunol. 18:241.
  8. Tassi, H. and M. Colonna (2005) J. Immunol. 175:7996.

Alternate Names

CD319, SLAMF7

Entrez Gene IDs

57823 (Human); 75345 (Mouse); 102133710 (Cynomolgus Monkey)

Gene Symbol

SLAMF7

UniProt

Q9NQ25

Additional CRACC/SLAMF7 Products

Product Documents for Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF

For research use only

Customer Reviews for Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF (1)

4 out of 5
1 Customer Rating
5 Stars
0%
4 Stars
100%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Customer Images

Showing  1 - 1 of 1 review Showing All
Filter By:
Clear Filters X
  • Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF
    Name: Anonymous
    Application: Binding assay/Protein-protein interaction
    Verified Customer | Posted 01/06/2026
    Recombinant Human CRACC/SLAMF7 Fc Chimera Protein, CF 1906-SF

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All

FAQs

No product specific FAQs exist for this product.

View all FAQs for Proteins and Enzymes